Overview

Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque Psoriasis

Status:
Withdrawn

Trial end date:
2018-01-31

Target enrollment:

Participant gender:

Summary

This is an open-label, safety study designed to assess the multiple-dose pharmacokinetics and potential for adrenal suppression following topical treatment with halobetasol propionate 0.05% spray applied twice-daily in adult patients with moderate to severe plaque psoriasis. At least 40 eligible patients with plaque psoriasis that satisfy all eligibility criteria will be enrolled into the study

Phase:

Phase 2

Details

Lead Sponsor:

Sun Pharmaceutical Industries Limited

Collaborator:

Novum Pharmaceutical Research Services

Treatments:

Clobetasol
Halobetasol